March 11, 2021 4:55pm

Pre-open indication results: 4 HITs and 4 MISS

News: Alnylam issues Inaugural Corporate Responsibility Summary … ... Shouldn’t Biostage (BSTG) get with the program, no clinical trial news after a year of IND clearance!  

Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

The Dow closed UP +188.57 points (+0.58%); the S&P closed UP +40.53 points (+1.04%) while the Nasdaq closed UP +329.84 points (+2.52 %)



Indexes climbed to record highs Thursday with the signing of fiscal aid/ stimulus bill giving sentiment a big boost.

The easing inflation worry helped support equities, with the cell and gene therapy sector moved higher. Expensive stocks, many of which are in “our universe’ or sector, have been highly sensitive to the rise in yields.


Data Docket: investors cheered a slightly better-than-expected reading on weekly jobless claims. The Labor Department reported that first-time filings for unemployment insurance in the week ended March 6 totaled a seasonally adjusted 712,000, below the estimate of 725,000.

  • The 10-year Treasury yield, which had retreated from its recent high of 1.6%, was little changed at 1.52% on Thursday.


RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: coming off last night's half-filled glass.  When you drink from a glass, the question of a refill is whether we drank too much or a clumsy move, I’m for a water before any next action? There are “some” undervalued equities out there … so drink the water, watch and wait.”


Pre-open indication results:  4 HITs <SELL: Biostage (BSTG -$0.13 with 1,153 shares – “pumped”); BUY: CRISPR Therapeutics (CRSP +$9.73), Homology Medicine (FIXX +$0.11); SELL into Strength:  Intellia Therapeutics (NTLA +$6.60) and 4 MISS < Cellectis SA (CLLS +$1.19), Fate Therapeutics (FATE +$7.81), bluebird bio (BLUE -$0.41), Global Blood Therapeutics (GBT +$1.38)


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Thursday opened positive at 28/4, 2 flats and 1 acquired, stayed positive at the mid-day to 26/7, 1 flat and 1 acquired, closing positive at 28/6 and 1 acquired;

There are clear winners and losers

Jumping with share pricing momentum:

  • CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), Ultragenyx (RARE) to name 5 of the 28 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), AxoGen (AXGN), bluebird bio (BLUE), Solid Bioscience (SLDB), Precigen (PGEN), biostage (BSTG) to name 6 of the 6 declining of the 35 covered


Key metrics:

  • Sector volume was LOW with 1 of the 28-upside having higher than the 3-month average volume with the volume of 1 of 6-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 28-upside were +0.77% (MESO) to +11.12% (NTLA) while the 6-downside ranges from -0.1.26% (BLUE) to -8.67% (BSTG);


Thursday’s (10 of 28) incline

  • CRISPR Therapeutics (CRSP +$9.73 after Wednesday’s -$1.48 and Tuesday’s +$12.01);
  • Alnylam Pharmaceuticals (ALNY +$8.30 after Wednesday’s -$3.00, Tuesday’s -$0.94 and Monday’s -$4.77);
  • Fate Therapeutics (FATE +$7.81 after Wednesday’s +$1.33, Tuesday’s +$9.36 and Monday’s -$4.49);
  • Ultragenyx (RARE +$6.89 after Wednesday’s -$4.26, Tuesday’s +$9.22 and Monday’s -$3.50);
  • Intellia Therapeutics (NTLA +$6.60 after Wednesday’s +$2.23, Tuesday’s +$10.55 and Monday’s -$5.22);
  • Sage Therapeutics (SAGE +$4.60 after Wednesday’s -$2.58, Tuesday’s +$2.98 and Monday’s -$2.08);
  • BioLife Solutions (BLFS +$3.27 after Wednesday’s +$0.45, Tuesday’s +$2.94 and Monday’s -$2.37);
  • Vericel (+$3.19);
  • Ionis Pharmaceuticals (IONS +$1.62 after Wednesday’s -$0.44);

Thursday’s (6 of 6) decliners:

  • ReNeuron (RENE.L -$3.00);
  • Solid Bioscience (SLDB -$0.47 after Wednesday’s -$0.77);
  • bluebird bio (BLUE -$0.41 after Wednesday’s +$2.44);
  • AxoGen (AXGN -$0.32);
  • Precigen (PGEN -$0.19 after Wednesday’s +$0.41);
  • Biostage (BSTG -$0.13 after Wednesday’s -$0.00, Tuesday’s -$0.10 and Monday’s -$0.03;

Closing Flat: 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • The stimulus is offsetting the virus which was also boosted by weekly jobless claims data, which pointed to a recovering U.S. labor market as vaccine rollouts have helped lead to economic re-openings.

Infection cases <Million>: never to forget …

  • Thursday 29.2 M cases,
  • Thursday’s death rate totaled 529,000 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +2.82% and XBI closed up +3.87%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.66 points or -2.93% at 21.90

Upside volume: low

  • Thursday: 1 out of the 28-upside had higher than the 3-month average volume;

Downside volume: low

  • Thursday: 1 out of the 6-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Thursday’s percentage (%) of the 28-upside were +0.77% (MESO) to +11.12% (NTLA) while the 6-downside ranges from -0.1.26% (BLUE) to -8.67% (BSTG);


March, the 3rd month of Q1/21:

Thursday closed positive with 28 advancers, 6 decliners and 1 acquired


The BOTTOM LINE: What went down leaving the sector half -empty…, went up,

Sustainability is the real issue in “this” market!

Markets are scary, frightening investors – volatilities basis is pure speculation i.e., gambling.

NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

There is always a shift going-on however, these last two (2) months and one (1) week continues to leave me … QUESTIONING each WEEK as I have said recently - my horizon on Monday is to meet on Friday.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice has been … trim and skim … if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.